Nichols, Wright W, Stone, Gregory G, Newell, Paul, Broadhurst, Helen, Wardman, Angela, MacPherson, Merran, Yates, Katrina, Riccobene, Todd, Critchley, Ian A and Das, Shampa ORCID: 0000-0002-2540-4816
(2018)
Ceftazidime-Avibactam Susceptibility Breakpoints Against Enterobacteriaceae and Pseudomonas aeruginosa.
Antimicrobial Agents and Chemotherapy, 62 (11).
e02590-e02517.
Text
AAC CAZ-AVI breakpoints author accepted.pdf - Author Accepted Manuscript Download (373kB) |
Abstract
Clinical susceptibility breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa for the ceftazidime-avibactam dosage regimen of 2000-500 mg every 8 hours (q8h) by 2-h intravenous infusion (adjusted for renal function) have been established by the FDA, CLSI and EUCAST as susceptible, MIC ≤8 mg/L, and resistant, MIC >8 mg/L. The key supportive data from PK/PD analyses, in vitro surveillance including molecular understanding of relevant resistance mechanisms, and efficacy in regulatory clinical trials, are collated and analyzed here.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | MIC breakpoints, ceftazidime-avibactam |
Depositing User: | Symplectic Admin |
Date Deposited: | 02 Nov 2018 09:01 |
Last Modified: | 19 Jan 2023 01:13 |
DOI: | 10.1128/aac.02590-17 |
Related URLs: | |
URI: | https://livrepository.liverpool.ac.uk/id/eprint/3028281 |